ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.Nature reviews. Clinical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeAccording to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC. EXPERIMENTAL
designConsecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab-pertuzumab plus taxane (2014-2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis.
resultsAmong 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2-2.5) and 0.0 (IQR, 0-0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray's P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray's P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073).
conclusionsBrain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.